A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer
Status:
Not yet recruiting
Trial end date:
2024-07-15
Target enrollment:
Participant gender:
Summary
This Phase II, global, single-arm study is designed to evaluate the efficacy, safety, and
pharmacokinetics of giredestrant monotherapy in participants with Grade 1 endometrioid
endometrial cancer.